Acalabrutinib

Acalabrutinib: A Targeted Treatment for Blood Cancers

Acalabrutinib is a prescription medication used to treat specific types of blood cancers. It is a targeted therapy, which means it works by blocking a specific protein involved in cancer cell growth and survival.

How Acalabrutinib Works

Acalabrutinib targets the Bruton tyrosine kinase (BTK) enzyme. BTK is a protein that helps cancer cells to grow and survive. By blocking BTK, acalabrutinib can help to stop the growth and spread of cancer cells.

Conditions Treated with Acalabrutinib

Acalabrutinib is approved to treat the following conditions:

• Chronic Lymphocytic Leukemia (CLL): A type of cancer that affects white blood cells.
• Mantle Cell Lymphoma (MCL): A type of non-Hodgkin’s lymphoma that affects B cells.

Key Benefits of Acalabrutinib

• Effective Treatment: Acalabrutinib has been shown to be an effective treatment for CLL and MCL, leading to improved outcomes for patients.
• Targeted Therapy: As a targeted therapy, acalabrutinib can help to reduce side effects compared to traditional chemotherapy.
• Improved Quality of Life: Acalabrutinib can help patients to maintain a better quality of life by managing symptoms and improving overall well-being.

Common Side Effects

Like all medications, acalabrutinib can cause side effects. Some common side effects include:

Side Effect	Description
Fatigue	Feeling tired or weak
Bleeding	Easy bruising or bleeding
Diarrhea	Loose stools
Joint Pain	Aching or soreness in the joints
Upper Respiratory Infections	Infections of the nose, throat, and lungs